Effect of recombinant FSH dosing following corifollitropin alfa in patients undergoing IVF/ICSI in a GnRH antagonist protocol: a randomized controlled dose-finding study.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517312-30-00

Enrollment

261

Registered

2024-10-04

Start date

2019-06-19

Completion date

Unknown

Last updated

2024-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subfertility in need of ICSI treatment

Brief summary

Mean serum P level on trigger day

Detailed description

Number of COCs retrieved, Number of patients who underwent FA, Clinical pregnancy rate, Ongoing pregnancy rate, Miscarriage rate, Live birth rate

Interventions

DRUGPuregon 900 IU/1.08 mL solution for injection

DRUGPuregon 300 IU/0.36 mL solution for injection

DRUGPuregon 600 IU/0.72 mL solution for injection

DRUGElonva 150 micrograms solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Mean serum P level on trigger day	—

Secondary

Measure	Time frame
Number of COCs retrieved, Number of patients who underwent FA, Clinical pregnancy rate, Ongoing pregnancy rate, Miscarriage rate, Live birth rate	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026